The Medical Technology Enterprise Consortium (MTEC) is excited to post this announcement for a Request for Project Information (RPI) focused onTraumatic Brain Injury Drug Treatment (TBI DT) – to rapidly conduct Phase 2 clinical trials on traumatic brain injury (TBI) drug candidates and identify at least one TBI drug candidate for advancement into a Phase 3 clinical trial. The end goal of the TBI DT program is a commercially-available TBI drug that is approved by the U.S. Food and Drug Administration (FDA) to treat moderate to severe TBI (i.e., patients presenting with a Glasgow Coma Scale (GCS) score of £ 12, or 13-15 with evidence of intracranial injury on imaging (CT or MRI) referable to trauma).
This RPI will be posted to the MTEC website (www.mtec-sc.org) and FedBizOpps (www.fbo.gov) to notify interested parties. Project Information Papers are due no later than Wednesday, 4 September 2019 at 5:00 PM ET. MTEC membership is NOT required for the submission of a Project Information Paper in response to this MTEC RPI.
Hyperlink for more information:
To view this solicitation, click here.
For inquiries regarding this announcement, please direct your correspondence to the following contacts:
- Technical questions and Membership questions
Dr. Lauren Palestrini, MTEC Director of Research, Lauren.Palestrini@officer.mtec-sc.org
- Administrative questions
Ms. Kathy Zolman, MTEC Interim Executive Director, Kathy.email@example.com
Filed Under: Funding Opportunities